RemeGen Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Yantai, Shandong and currently employs 2,999 full-time employees. The company went IPO on 2020-11-09. RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The firm focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The firm's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The firm mainly operates its businesses in the domestic and overseas markets.
09995.HK stock price ended at $92.9 on 星期二, after dropping 2.42%
On the latest trading day Jan 20, 2026, the stock price of 09995.HK fell by 2.42%, dropping from $95.30 to $92.90. During the session, the stock saw a volatility of 4.13%, with prices oscillating between a daily low of $92.00 and a high of $95.80. On the latest trading day, the trading volume for 09995.HK rose by 803.0K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 3.7M shares were traded, with a market value of approximately $19.3B.